摘要
背景与目的为了提高晚期肺癌的化疗效果,实行个体化治疗,筛选和鉴定肺癌细胞抗癌药物敏感性基因具有重要临床意义。本研究比较了非小细胞肺癌(NSCLC)和永生化人支气管上皮细胞(BET2A)细胞株抗癌药物敏感性相关基因的差异表达,以寻找与抗癌药物敏感性相关的基因。方法应用cDNAmacroarray技术,对6株NSCLC和BET2A细胞株的抗癌药物敏感性相关基因进行差异表达分析,RTPCR技术验证滤膜杂交结果。结果在1291个候选基因中筛选出73个差异表达基因,其中45个基因表达上调,28个基因表达下调。RTPCR验证结果与cDNAmacroarray检测结果一致。结论抗癌药物敏感性相关基因的差异表达可能是药物敏感性产生不同的原因之一。本研究结果为逆转肺癌多药耐药性提供了理论基础和新靶点,并为临床新药开发及个体化治疗提供了实验依据。
Background and objective In order to enhance the chemotherapeutic efficacy of advanced lung cancer and to practise the individualized treatment, it is necessary to find out the difference of anticancer drug-sensitivity in lung cancer cells. Comparing the array profile of related gene of anticancer drug-sensitivity between non-small cell lung cancer (NSCLC) cell lines and immortal human bronchial epithelial cell line BET2A, the difference of expression of related genes of anticancer drug sensitivity was detected. Methods With the technique of cDNA macroarray, the different related gene proceeding of anticancer drug sensitivity expression was analysed in 6 NSCLC cell lines and BET2A cell line. RT-PCR was used to reconfirm the results. Results Seventy-three genes which were differentially expressed were found from 1291 candidate genes, and there were 45 genes upregulated, and 28 genes downregulated. The results of RT-PCR were consistent with those of cDNA macroarray. Conclusion The main reason of different sensitivity might be the difference of related gene of anticancer drug sensitivity expression. The results of this study provide new targets for reversing multiple drug-resistance, and they also provide experimental evidence to develop some new drugs and to realize the individualized treatment clinically.
出处
《中国肺癌杂志》
CAS
2005年第3期163-169,共7页
Chinese Journal of Lung Cancer
基金
哈尔滨市科学技术局哈尔滨市留学回国人员基金项目(No.2003AFLXJ009)资助
